MP-AzeFlu provides rapid and effective allergic rhinitis control in real life

A pan-European study

Ludger Klimek, Claus Bachert, Par Stjarne, Ralph Dollner, Petter Larsen, Peter Haahr, Ioana Agache, Glenis Scadding, David Price

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma has endorsed the visual analog scale (VAS) as the AR control language and incorporated it into a new AR treatment algorithm. Concurrently, the Respiratory Effectiveness Group and the European Academy of Allergy and Clinical Immunology are striving to improve the quality of published real-life AR research. Our aim was to assess the effectiveness of MP-AzeFlu by using a VAS in a well-designed, real-life, pan-European study. Methods: A total of 2988 patients (aged ≥ 12 years) with Allergic Rhinitis and its Impact on Asthma defined moderate-to-severe AR from Germany, Sweden, Romania, United Kingdom, Denmark, and Norway were included. Patients (except from the United Kingdom) assessed symptom severity by using a VAS from 0 mm (not at all bothersome) to 100 mm (very bothersome) on days 0, 1, 3, 7, and the last visit (∼day 14) in the morning before MP-AzeFlu use. Patients' perceived level of disease control was assessed on day 3. A VAS score cutoff on day 3 for “well controlled” was determined, and the proportion of patients who achieved this response was calculated. Results: MP-AzeFlu was associated with a mean VAS score reduction from 73.7 mm at baseline to 23.4 mm by the last visit. This reduction was significant (p < 0.001) compared with baseline from day 1 and sustained until the last day of the study. By day 3, 50.3% of patients considered their symptoms well controlled; 18.2, 40.0, 66.6, and 75.9% of the patients achieved the ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7 and the last day, respectively. The results were consistent across countries, age, phenotype, and severity. Conclusion: MP-AzeFlu provided effective and rapid symptom control in a real-life pan-European setting and aligned with the European Union, Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma, the Respiratory Effectiveness Group, and the European Academy of Allergy and Clinical Immunology objectives, supporting MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR.
Original languageEnglish
Pages (from-to)376-386
Number of pages11
JournalAllergy and Asthma Proceedings
Volume37
Issue number5
Early online date12 Aug 2016
DOIs
Publication statusPublished - 1 Sep 2016
EventMeeting of the European-Academy-of-Allergy-and-Clinical-Immunology - Vienna, Austria
Duration: 11 Jun 201615 Jun 2016

Fingerprint

Visual Analog Scale
Asthma
European Union
Allergy and Immunology
Allergic Rhinitis
Romania
Denmark
Norway
Sweden
Germany
Language
Phenotype
Therapeutics
Research
Pharmaceutical Preparations

Cite this

MP-AzeFlu provides rapid and effective allergic rhinitis control in real life : A pan-European study. / Klimek, Ludger; Bachert, Claus; Stjarne, Par; Dollner, Ralph; Larsen, Petter; Haahr, Peter; Agache, Ioana; Scadding, Glenis; Price, David.

In: Allergy and Asthma Proceedings, Vol. 37, No. 5, 01.09.2016, p. 376-386.

Research output: Contribution to journalArticle

Klimek, L, Bachert, C, Stjarne, P, Dollner, R, Larsen, P, Haahr, P, Agache, I, Scadding, G & Price, D 2016, 'MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study', Allergy and Asthma Proceedings, vol. 37, no. 5, pp. 376-386. https://doi.org/10.2500/aap.2016.37.3979
Klimek, Ludger ; Bachert, Claus ; Stjarne, Par ; Dollner, Ralph ; Larsen, Petter ; Haahr, Peter ; Agache, Ioana ; Scadding, Glenis ; Price, David. / MP-AzeFlu provides rapid and effective allergic rhinitis control in real life : A pan-European study. In: Allergy and Asthma Proceedings. 2016 ; Vol. 37, No. 5. pp. 376-386.
@article{2a2de04572a541c08e02ba01e423f8e7,
title = "MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study",
abstract = "Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma has endorsed the visual analog scale (VAS) as the AR control language and incorporated it into a new AR treatment algorithm. Concurrently, the Respiratory Effectiveness Group and the European Academy of Allergy and Clinical Immunology are striving to improve the quality of published real-life AR research. Our aim was to assess the effectiveness of MP-AzeFlu by using a VAS in a well-designed, real-life, pan-European study. Methods: A total of 2988 patients (aged ≥ 12 years) with Allergic Rhinitis and its Impact on Asthma defined moderate-to-severe AR from Germany, Sweden, Romania, United Kingdom, Denmark, and Norway were included. Patients (except from the United Kingdom) assessed symptom severity by using a VAS from 0 mm (not at all bothersome) to 100 mm (very bothersome) on days 0, 1, 3, 7, and the last visit (∼day 14) in the morning before MP-AzeFlu use. Patients' perceived level of disease control was assessed on day 3. A VAS score cutoff on day 3 for “well controlled” was determined, and the proportion of patients who achieved this response was calculated. Results: MP-AzeFlu was associated with a mean VAS score reduction from 73.7 mm at baseline to 23.4 mm by the last visit. This reduction was significant (p < 0.001) compared with baseline from day 1 and sustained until the last day of the study. By day 3, 50.3{\%} of patients considered their symptoms well controlled; 18.2, 40.0, 66.6, and 75.9{\%} of the patients achieved the ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7 and the last day, respectively. The results were consistent across countries, age, phenotype, and severity. Conclusion: MP-AzeFlu provided effective and rapid symptom control in a real-life pan-European setting and aligned with the European Union, Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma, the Respiratory Effectiveness Group, and the European Academy of Allergy and Clinical Immunology objectives, supporting MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR.",
author = "Ludger Klimek and Claus Bachert and Par Stjarne and Ralph Dollner and Petter Larsen and Peter Haahr and Ioana Agache and Glenis Scadding and David Price",
note = "ACKNOWLEDGMENTS We thank Ruth Murray, Ph.D., for assistance with drafting, editing, and reviewing this manuscript. Funding was provided by Meda, Solna, Sweden L. Klimek has received grants, honorariums, and consulting fees from Meda and Solna. The authors have no conflicts of interest to declare pertaining to this article",
year = "2016",
month = "9",
day = "1",
doi = "10.2500/aap.2016.37.3979",
language = "English",
volume = "37",
pages = "376--386",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "5",

}

TY - JOUR

T1 - MP-AzeFlu provides rapid and effective allergic rhinitis control in real life

T2 - A pan-European study

AU - Klimek, Ludger

AU - Bachert, Claus

AU - Stjarne, Par

AU - Dollner, Ralph

AU - Larsen, Petter

AU - Haahr, Peter

AU - Agache, Ioana

AU - Scadding, Glenis

AU - Price, David

N1 - ACKNOWLEDGMENTS We thank Ruth Murray, Ph.D., for assistance with drafting, editing, and reviewing this manuscript. Funding was provided by Meda, Solna, Sweden L. Klimek has received grants, honorariums, and consulting fees from Meda and Solna. The authors have no conflicts of interest to declare pertaining to this article

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma has endorsed the visual analog scale (VAS) as the AR control language and incorporated it into a new AR treatment algorithm. Concurrently, the Respiratory Effectiveness Group and the European Academy of Allergy and Clinical Immunology are striving to improve the quality of published real-life AR research. Our aim was to assess the effectiveness of MP-AzeFlu by using a VAS in a well-designed, real-life, pan-European study. Methods: A total of 2988 patients (aged ≥ 12 years) with Allergic Rhinitis and its Impact on Asthma defined moderate-to-severe AR from Germany, Sweden, Romania, United Kingdom, Denmark, and Norway were included. Patients (except from the United Kingdom) assessed symptom severity by using a VAS from 0 mm (not at all bothersome) to 100 mm (very bothersome) on days 0, 1, 3, 7, and the last visit (∼day 14) in the morning before MP-AzeFlu use. Patients' perceived level of disease control was assessed on day 3. A VAS score cutoff on day 3 for “well controlled” was determined, and the proportion of patients who achieved this response was calculated. Results: MP-AzeFlu was associated with a mean VAS score reduction from 73.7 mm at baseline to 23.4 mm by the last visit. This reduction was significant (p < 0.001) compared with baseline from day 1 and sustained until the last day of the study. By day 3, 50.3% of patients considered their symptoms well controlled; 18.2, 40.0, 66.6, and 75.9% of the patients achieved the ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7 and the last day, respectively. The results were consistent across countries, age, phenotype, and severity. Conclusion: MP-AzeFlu provided effective and rapid symptom control in a real-life pan-European setting and aligned with the European Union, Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma, the Respiratory Effectiveness Group, and the European Academy of Allergy and Clinical Immunology objectives, supporting MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR.

AB - Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma has endorsed the visual analog scale (VAS) as the AR control language and incorporated it into a new AR treatment algorithm. Concurrently, the Respiratory Effectiveness Group and the European Academy of Allergy and Clinical Immunology are striving to improve the quality of published real-life AR research. Our aim was to assess the effectiveness of MP-AzeFlu by using a VAS in a well-designed, real-life, pan-European study. Methods: A total of 2988 patients (aged ≥ 12 years) with Allergic Rhinitis and its Impact on Asthma defined moderate-to-severe AR from Germany, Sweden, Romania, United Kingdom, Denmark, and Norway were included. Patients (except from the United Kingdom) assessed symptom severity by using a VAS from 0 mm (not at all bothersome) to 100 mm (very bothersome) on days 0, 1, 3, 7, and the last visit (∼day 14) in the morning before MP-AzeFlu use. Patients' perceived level of disease control was assessed on day 3. A VAS score cutoff on day 3 for “well controlled” was determined, and the proportion of patients who achieved this response was calculated. Results: MP-AzeFlu was associated with a mean VAS score reduction from 73.7 mm at baseline to 23.4 mm by the last visit. This reduction was significant (p < 0.001) compared with baseline from day 1 and sustained until the last day of the study. By day 3, 50.3% of patients considered their symptoms well controlled; 18.2, 40.0, 66.6, and 75.9% of the patients achieved the ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7 and the last day, respectively. The results were consistent across countries, age, phenotype, and severity. Conclusion: MP-AzeFlu provided effective and rapid symptom control in a real-life pan-European setting and aligned with the European Union, Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma, the Respiratory Effectiveness Group, and the European Academy of Allergy and Clinical Immunology objectives, supporting MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR.

U2 - 10.2500/aap.2016.37.3979

DO - 10.2500/aap.2016.37.3979

M3 - Article

VL - 37

SP - 376

EP - 386

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 5

ER -